Topic: multiple sclerosis
Investors are clamoring for a CVR created in the BMS-Celgene deal, but it will only pay off if the FDA approves three hot pipeline projects.
A small group of physicians expressed little interest in new MS drugs from Novartis, Merck KGaA and Biogen but favored a repurposed therapy.
Mavenclad helped Merck KGaA's neuroscience portfolio grow 2.3% in the third quarter, even in the face of Rebif's 15% year-over-year sales decline.
Biogen's MS business has been treading water and its top-selling Tecfidera might face early generics. But now a follow-up med has nabbed FDA approval.
Genentech has launched its first consumer campaign for multiple sclerosis drug Ocrevus, with emphasis on a particular cohort of patients: millennials.
Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.
Roche is steamrolling with Ocrevus, and to maintain that lead, its touting long-term data that show the earlier it’s given, the better patients do.
New data shows a significant reduction in relapse rates in patients taking Novartis' repurposed cancer drug ofatumumab.
A post hoc analysis found 75% of patients showed no increase in disability five years after treatment with Mavenclad.
Novartis is working to change doctors’ “psychology” around SPMS treatment. And new disability data for its drug, Mayzent, should help its case.